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The long-term treatment of chronic uremic patients with intermittent
dialysis has led to an increase in the life span of these individuals. A num-
ber of low-molecular-weight compounds accumulate in body fluids of
uremic patients and may contribute to the toxic features of uremia. Many
of these are removed by hemodialysis. Most frequently hemodialysis is
accompanied by improvement of the patient as manifested by reduction of
central nervous system symptoms and other salutary clinical effects."' It
has been shown that the concentration of organic acids is elevated in the
blood of uremic patients. The increased concentration of these acids above
the normal value of 6 meq/l. appears to correlate with the clinical signs
and symptoms of uremia.'
Investigators have analyzed uremic serum and dialysis fluid for toxicity
in various in vitro model systems. Hicks, Young, and Wootton' have shown
that several enzymes found in the brain are inhibited by some of the
aromatic acids known to be present in dialysis fluid obtained during the
treatment of patients suffering from renal failure. Morgan, et al.' have
demonstrated that an ultrafiltrate of uremic plasma inhibits rabbit heart
lactic dehydrogenase in an in titro system. In other studies Morgan and
Morgan! have indicated that dialysates of uremic plasma have an inhibitory
effect on the glycolytic pathway of erythrocytes. Markson and Rennie' have
shown that uremic serum inhibits the maturation of normoblasts in tissue
cultures of bone marrow. It is known that children with uremia fail to
grow and that treatment by hemodialysis restores ability to grow.1 A bio-
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assay was developed to test dialysates for inhibitory action against protein
synthesis.
In our study, fractions obtained from hemodialysates of uremic patients
were tested for their effect on protein synthesis. The in vitro incorporation
of tritiated leucine into protein by rat liver homogenates was the model
system chosen. This in vitro assay was selected because it allowed the study
of the small amounts of materials that were obtained from fractions of
hemodialysate.
MATERIALS AND METHODS
Hemodialysis fluid was obtained during the treatment of uremic patients on the twin
coil, disposable artificial kidney. The patients studied had uremia manifested by
azotemia and central nervous system signs and symptoms related to the uremia. Five
patients studied required treatment with hemodialysis to keep them alive. Two were
treated by peritoneal dialysis. The compounds studied were derived from these
dialysis fluids. Usually, 20 to 40 liters were taken from the first 100-liter bath used
for dialysis. The fluid was concentrated in vacuo, acidified and extracted with butanol
to obtain the acid fraction. It was then subjected to fractionation in a 20- or 100-tube
counter-current distribution apparatus8 using water and isobutanol as the solvents.
The contents of each tube were titrated to pH 8 to determine the amount of acids
present and then chromatographed on Whatman #1 paper in various solvent systems.
Fractions were eluted from the paper after fluorescing and absorbing bands were
identified on the chromatograms. Details of the purification procedure are given
in earlier papers."'0
The amino-acid-incorporating system designated by Sokoloff and Kaufmann as
procedure A was modified slightly and used in these studies. Cell-free rat liver
homogenates were prepared as described by Sokoloff and Kaufmann.' The incubation
medium contained 75 psmol. of sucrose, 0.5 umol. of adenosine monophosphate, 10
,umol. of tris(hydroxymethyl)aminomethane buffer (pH 7.4), 2.5 ,umol. MgCl2, 25
,mol. a-ketoglutarate and 5 ,ucuries of DL 3H leucine (specific activity 5,000 ,c/
jumol.). Each reaction flash contained 0.25 ml. of liver homogenate. The samples dis-
solved in water or controls (which consisted of water only) were added to bring the
reaction to a final volume of 0.85 ml. The reaction mixtures were shaken in 20 ml.
penicillin bottles for 30 minutes at 370 C. in a water bath.
Incorporation of 3H leucine was measured by the "disc" method devised by Mans
and Novelli.' A 0.1 ml. aliquot of reaction mixture was pipetted onto a 2.5 cm. disc
of Whatman #3MM filter paper. After the protein solution was absorbed into the
filter paper, the disc was plunged into ice cold 10 per cent trichloroacetic acid (TCA)
containing 0.1M 12C DL leucine as carrier. In this wash and in all subsequent washes
approximately 5 ml. of solution were used for every disc. All discs from each experi-
ment were washed in batches. Discs were allowed to remain in contact with the
carrier leucine for at least one hour. The batch of discs was then washed in 5 per cent
TCA for 15 minutes at room temperature. They were then washed in 5 per cent TCA
at 90° C. for 30 minutes and again in 5 per cent TCA at room temperature for 15
minutes. Further washing was accomplished by placing the discs in a solution made
from equal volumes of diethyl ether and ethyl alcohol at 37° C. for 30 minutes. This
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wash was repeated. Finally, the batch was washed three times in ether to remove
the remaining alcohol and water. The filter paper discs were dried overnight at room
temperature. The isotope on the discs was counted directly in a liquid scintillation
counter (Packard Tricarb Model 314E or Nuclear-Chicago Model 720) using 5 ml.
of 1 per cent2,5-diphenyloxazole (PPO) and 0.4 per cent p-bis[2-(5-phenyloxazolyl)]-
benzene (POPOP). Sufficient counts were taken to obtain a counting error of less
than three per cent. Three control discs were run concurrently with each experiment.
The net counts obtained from the controls varied from 500 to 700 counts per minute.
The controls in any one experiment agreed within five per cent. The data are
expressed as per cent of the controls run concurrently in each experiment.
TABLE 1. INCORPORATION OF LEUCINE IN THE PRESENCE OF 10 PER CENT OF
MATERIAL FROM A 20-TUBE FRACTIONATION OF HEMODIALYSATE













In the first studies, five liters of dialysis fluid were concentrated,
extracted, and processed by counter-current fractionation in a 20-tube
instrument. Ten per cent of the dry residue of alternate tubes of the
counter-current run was used for assay. The results are shown in Table 1.
The region of maximal inhibition was seen in tube 6, which would be
equivalent to tube 30 in a 100-tube counter-current fractionation.
Material from tubes 4, 6, and 8 representing the area of the counter-
current fractionation that showed maximal suppression of uptake was
titered to study the effects of decreasing amounts of fractions of dialysis
fluid on amino acid incorporation into protein. The data are shown in
Table 2.
These data agree with the findings in Table 1 showing maximal inhibition
in tube 6. At every comparable concentration, incorporation was lower in
tube 6 than in tubes 4 or 8. Incorporation was lowest when fractions were
in greatest concentration. Subsequent studies were performed on material
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TABLE 2. TiTER OF CONTENTS OF TUBES THAT HAD SHOWN MAXIMAL INHIBITION
Per cent uptake (Control = 100)
Per cent of total contents used Tube 4 Tube 6 Tube 8
10 37 32 37
5 53 37 66
1 80 56 97
0.2 92 75 106
from this region of the counter-current fractionation. In an effort to sep-
arate the compounds present in this area, 16 per cent of the contents of
tube 6 was placed on chromatographic paper (Whatman #1) and devel-
oped in an isopropanol-ammonia system, dried and redeveloped in the same
solvent. Eleven equal segments were cut from this paper, eluted, dried and
reconstituted with water. All the material was assayed as above. The results
in Table 3 show that maximal decrease in amino acid incorporation was
observed in the region of Rf 0.36 to 0.54. Every bioassay performed had
a water control. In this experiment if the control value was inadvertently
too low, the base line for comparison of amino acid uptake should be
drawn higher than 100 per cent. However, the possible presence of
stimulating factors cannot be excluded. Table 3 expresses relative uptake
caused by fractions from a single chromatogram (double pass of solvents).
These data are valuable in demonstrating the area of the chromatogram
TABLE 3. INCORPORATION OF LEUCINE IN THE PRESENCE OF ELUATES OF
CHROMATOGRAM FRACTIONS OF 16 PER CENT OF TUBE 6 OF A 20-TUBE
COUNTER-CURRENT FRACTIONATION
Eluate fraction Rf* Per cent uptake (Control = 100)
1 0.00- 0.09 113
2 0.09- 0.18 124
3 0.18- 0.27 115
4 0.27- 0.36 95
5 0.36- 0.45 88
6 0.45- 0.54 78**
7 0.54- 0.63 108
8 0.63- 0.72 93
9 0.72- 0.81 100
10 0.81- 0.90 105
11 0.90- 1.00 116
* This chromatogram was developed with the descending solvent, dried and re-
developed for a second pass in the same solvent.
** Minimum uptake.
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where inhibition occurs. The difference in amounts used, differences in
fractionation and vagaries of bioassay explain the differences between the
data in Tables 1 and 3. However, demonstration of inhibition was apparent
in every experiment.
In order to obtain more material of greater purity, 21 liters of dialysate
were extracted and fractionated in a 100-tube counter-current apparatus.
Tube 30 of this fractionation is comparable to tube 6 of a 20-tube counter-
current fractionation. A chromatogram (single pass) containing 10 per cent
of the contents of tube 30 was cut into five equal bands. The results seen
in Table 4 show the presence of inhibitory material at Rf 0.0 to 0.4. The
TABLE 4. INCORPORATION OF LEUCINE IN THE PRESENCE OF ELUATES OF
CHROMATOGRAM FRACTIONS OF 10 PER CENT OF TUBE 30 OF A
100-TUBE COUNTER-CURRENT FRACrIONATION
Per cent uptake






* Single pass of solvent on this chromatogram.
** Minimum uptake.
higher Rf of active material in Table 3 is the result of a double pass on
the chromatogram. The chromatograms of counter-current tubes close to
tube 30 were studied further in order to determine which compounds were
responsible for inhibiting the incorporation of 3H leucine. Several strongly
absorbing bands on the chromatograms were observed in ultraviolet light.
These were sharpened by multiple passes in the isopropanol solvent system,
and the compounds were further isolated by using other solvent systems.
The major components isolated in this region were lactic acid and
N-methyl-2-pyridone-5-carboxamide (2-PY amide). When 2-PY amide
was tested at concentrations of 2 x 10-8 moles per liter, no inhibition was
noted. This concentration of 2-PY amide was greater than that which had
been tested from the paper chromatograms. Similarly, lactic acid did not
inhibit protein synthesis at 1 x 10-1 molar concentration. This level was also
greater than the amount tested from the chromatograms. Since these com-
pounds in chemically pure form did not inhibit the system, it was assumed
that they were not responsible for the effects observed when material from
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the chromatograms was tested. Subsequently, an ultraviolet absorbing com-
pound from the same region of the chromatogram was isolated and found to
be N-methyl-2-pyridone-5-formamidoacetic acid (2-PY hippurate)." When
this compound was synthesized in our laboratory and tested, it was found
to inhibit at 1 x 10-4 molar concentration. The amount of 2-PY hippurate
present appeared to account for the inhibition found in paper chromatogram
fractions. We found 2-PY hippurate in four patients. The pure compound
isolated by counter-current fractionation and several runs on chromato-
grams was quantified by its ultraviolet absorbance. The amount of 2-PY
hippurate quantified in four dialysates ranged from 4.2 to 86 ,ug/L. It was
TABLE 5. EFFFCTs OF 2-PY AMIDE, 2-PY HIPPuRATE, AND 2-PY ACID ON
3H LEUCINE INCORPORATION INTO PROTEIN
Per cent uptake (Control = 100)
Molar 2-PY amide 2-PY hippurate 2-PY acid
concentration Run I Run II Run I Run II Run I Run II
1 x 10' 133 116 49 55 58 14
6 x 10-' 103 114 68 46 65 53
3 x 10' 96 117 72 75 79 62
1 X 104 99 98 82 59 90 46
estimated (by assuming that half the 2-PY hippurate in the uremic patient
appeared in the dialysis fluid and that the compound was uniformly dis-
tributed in body water) that these four uremic patients might have from
2 to 41 jug of 2-PY hippurate in 100 ml. of blood.'3
Another compound with a similar ultraviolet absorption spectrum was
found in tube 61, a less polar region of the counter-current distribution, and
identified as N-methyl-2-pyridone-5-carboxylic acid (2-PY acid).' lhis
compound was found in the dialysate from one patient. Synthetic 2-PY
acid also inhibited protein synthesis at 1 x 10-4 molar concentration. Normal
plasma, cerebrospinal fluid and hemodialysate from a barbiturate poisoning
(with normal kidneys) showed no 2-PY acid or 2-PY hippurate.
The effects of the three compounds were studied in two separate experi-
ments at four different concentrations. The data, seen in Table 5, show
that 2-PY acid and 2-PY hippurate strongly inhibited protein synthesis.
The other compound, 2-PY amide, appeared to stimulate uptake at some
of the levels tested.
These compounds, 2-PY amide, 2-PY acid, and 2-PY hippurate (see
Fig. 1), have similar ultraviolet absorption characteristics. The spectrum
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FIG. 1. Formulas of (1) N-methyl-2-pyridone-5-carboxylic acid (2-PY acid);
(2) N-methyl-2-pyridone-5-carboxamide (2-PY amide); and (3) N-methyl-2-
pyridone-5-formamidoacetic acid (2-PY hippurate).
of 2-PY amide shows absorption maxima at 260 and 290 my.1' The
absorption does not change with pH as demonstrated by Chang and
Johnson.' The spectrum of 2-PY hippurate is identical with that of the
amide, but the spectrum of 2-PY acid shifts with changes in pH as shown
by Lindenblad, et al.' The Rf's of 2-PY amide, 2-PY acid, and 2-PY
hippurate in isopropanol: ammonia: water (8: 1: 1) are 0.44, 0.20, and
0.30 respectively. In benzene: propionic acid: water (125: 72: 3) their
Rf's are 0.50, 0.74, and 0.18 respectively.
Several other pure compounds known to be present in dialysis fluid were
studied. The results with some of these are shown in Table 6. These
organic acids were not inhibitory at the concentrations studied.
DISCUSSION
Clinical improvement usually results from the treatment of uremic
patients either with the artificial kidney or with peritoneal dialysis. This
suggests that the small molecules which are removed by dialysis contribute
to the symptomatology in uremia. Various research workers4' have shown
that metabolic processes are impaired by factors present in the serum of
TABLE 6. EFFECT OF P-HYDROXYBENZOIc ACID, O-HYDROXYPHENYL-
ACETIC ACID, AND P-HYDROXYPHENYLACETIc ACID ON
3H LEUCINE INCORPORATION INTO PROEIN
Per cent uptake (Control = 100)
p-hydroxybenzoic o-hydroxyphenyl- p-hydroxyphenyl-
Molar concentration acid acetic acid acetic acid
I x 10 92 89 102
1 x 108 99 102 96
1 x 10 97 86 108
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uremic patients. For the most part, these investigators have been unable to
charactertize them chemically.
The data obtained here indicate that protein synthesis, as measured by
an in vitro amino acid incorporation system, is impaired by crude fractions
isolated from uremic dialysis fluid. It was possible to extend these observa-
tions to specific organic compounds, present in dialysis fluid, that decreased
the incorporation of 3H leucine into liver homogenates. Two compounds,
pure 2-PY hippurate and 2-PY acid, isolated from dialysis fluid, inhibited
the system. Another related metabolite of nicotinic acid, 2-PY amide, did
not inhibit protein synthesis at equimolar concentrations. Minor alterations
of chemical structure profoundly affect the assay system used.
It is difficult to correlate findings obtained in vitro using cell-free systems
with the complex deranged metabolism of a chronic disease such as uremia.
It has been shown, however, that small organic anions similar to those
studied are capable of entering human erythrocytes." Presumably, they
can enter other cells.
The concentration of 2-PY hippurate observed to inhibit protein syn-
thesis in the assay system was about 50 to 100 times the concentration
estimated to be present in the body fluids of four patients. If it is noxious
in zivo, sufficient time exists during the uremic syndrome for diffusion into
cells where it could perhaps exert a similar effect to the in vitro one.
If it exerts a deleterious effect, it could be because (1) it concentrates
intracellularly, (2) it works over a long period of time (one to three weeks
or more), or (3) it has an additive or synergistic effect with other com-
pounds that accumulate in uremia. Although protein synthesis was used as
a bioassay for adverse effects of 2-PY hippurate, in vivo metabolic con-
sequences from it might be difficult to discern.
SUMMARY
An in vitro assay system which measures the incorporation of 3H leucine
into protein has been used to demonstrate that fractions of dialysis fluid
from uremic patients inhibit amino acid incorporation into protein. By
analyzing consecutively the areas that showed greatest inhibition of incor-
poration, 2-PY hippurate was isolated and identified. This compound and
another, 2-PY acid, found in a uremic patient, strongly inhibited the
system. Another closely related compound, 2-PY amide, which traveled in
a similar manner to 2-PY hippurate, did not affect the system. This assay
may be of value in determining the toxic components present in uremia.
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